New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
11:48 EDTSHPG, ABBVShire says AbbVie proposal contains no new information
Shire (SHPG) notes today's announcement by AbbVie (ABBV) repeating its proposal of May 30, which comprised GBP 20.44 in cash and 0.7988 AbbVie shares per Shire share. Shire says, "Today's announcement by AbbVie contains no new proposal and provides no material new information. The Board of Shire has already considered this Proposal in detail and unanimously rejected it, concluding that it fundamentally undervalued the Company and its prospects. Shareholders are strongly advised to take no action in relation to the Proposal. There can be no certainty that any firm offer will be made, nor as to the terms on which any firm offer might be made. This statement is being made by Shire without the prior agreement or approval of AbbVie."
News For SHPG;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 15, 2014
12:36 EDTABBV, SHPGOn The Fly: Midday Wrap
Subscribe for More Information
10:48 EDTSHPG, ABBVShire tanks with AbbVie calling board meeting over merger
Subscribe for More Information
10:02 EDTSHPGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:57 EDTABBVLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
09:20 EDTSHPG, ABBVOn The Fly: Pre-market Movers
Subscribe for More Information
09:11 EDTSHPGShire upgraded to Buy from Fair Value at CRT Capital
Subscribe for More Information
07:30 EDTABBV, SHPGAbbVie review of Shire deal an 'unwelcome surprise,' says Jefferies
Subscribe for More Information
06:58 EDTABBV, SHPGAbbVie volatility elevated into reconsidering Shire merger
Subscribe for More Information
06:55 EDTABBV, SHPGShire volatility elevated into AbbVie reconsidering merger recommendation
Subscribe for More Information
05:34 EDTABBV, SHPGShire says AbbVie should proceed with recommended offer
Subscribe for More Information
October 14, 2014
19:59 EDTABBVAbbVie down nearly 2% after board reconsiders Shire merger
19:50 EDTSHPGShire down nearly 6% following AbbVie reconsidering merger recommendation
Subscribe for More Information
19:48 EDTSHPG, ABBVAbbVie board reconsidering recommendation to holders to accept Shire merger
Subscribe for More Information
19:46 EDTSHPG, ABBVAbbVie board reconsidering recommendation to holders to accept Shire merger
Subscribe for More Information
12:41 EDTABBVGilead retreats following Johnson & Johnson comments on HCV drug
Shares of Gilead (GILD), which has developed a hepatitis C treatment, are retreating after Johnson & Johnson (JNJ) said it would seek to make its own hepatitis C treatment accessible and competitive. Some investors believe that Johnson & Johnson's comments suggest that it will cut the price of its hepatitis C drug. WHAT'S NEW: Johnson & Johnson said on its earnings conference call today that it was "committed" to its treatment for hepatitis C virus, or HCV. The company added that it intends to remain competitive in the space and would look to make its HCV treatment, Olysio, accessible. In a separate development today, The Wall Street Journal reported that Abbvie (ABBV), which also has an HCV treatment, may have to consider pricing its HCV drug more aggressively after Gilead received FDA approval for Harvoni, the first combination pill approved to treat chronic HCV genotype 1 infection. One analyst quoted by The Journal, Roger Longman, said that AbbVie should consider pricing its drug at $76,000 for a 12 week regimen, representing a 20% discount to Harvoni, which will be priced at $94,500 for a full 12 week regimen. ANALYST REACTION: In a note to investors earlier today, RBC Capital analyst Michael Yee wrote that the weakness in Gilead's stock today has created a buying opportunity. Johnson & Johnson probably can't reduce the price of its Olysio drug much, since it is often used in combination with Gilead's Sovaldi, which costs $84,000 for 12 weeks, RBC Capital analyst Michael Yee wrote in a note to investors today. The price of AbbVie's treatment is unlikely to be much below Sovaldi's price, the analyst stated. WHAT'S NOTABLE: Gilead, along with a number of other drug companies, may also be under pressure because Ireland is reportedly closing its "Irish Double" tax loophole. Gilead is one of the companies that currently benefits from the "Irish Double," but Yee says that closing the loophole should only have a "minimal" impact on Gilead. PRICE ACTION: In early afternoon trading, Gilead fell 3.3% to $98.10, AbbVie gained 1.7% to $54.53 and Johnson & Johnson lost 0.6% to $98.52.
10:51 EDTABBVGilead weakness a buying opportunity, says RBC Capital
Subscribe for More Information
10:05 EDTABBVAbbVie could cause Hep C price tipping point with aggressive pricing, WSJ says
Subscribe for More Information
October 13, 2014
09:23 EDTABBVAbbVie's Humira for hidradenitis suppurativa meets Phase 3 trial endpoint
AbbVie announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of Humira in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa, specifically the number of abscesses and inflammatory nodules. The results of this study, in combination with previously presented results from PIONEER I, will contribute to worldwide regulatory filings for an expanded use of Humira, which is not currently approved by regulatory authorities for the treatment of HS.
07:39 EDTABBVPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
07:37 EDTABBVAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use